Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 219Recurrence 23Neoplasms, Plasma Cell 15Immunoglobulin Light-chain Amyloidosis 14Neoplasms 12Lymphoma, Non-Hodgkin 6Smoldering Multiple Myeloma 5Leukemia, Myeloid, Acute 4Plasmacytoma 3Paraproteinemias 3Leukemia, Plasma Cell 3Hematologic Neoplasms 3Hematologic Diseases 3Amyloidosis 3Neoplasm, Residual 2Hodgkin Disease 2Disease 2Corneal Diseases 2Blood Protein Disorders 2Acute Kidney Injury 2Triple Negative Breast Neoplasms 1Renal Insufficiency 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Personal Satisfaction 1Patient Satisfaction 1Patient Preference 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1

Interventions

Dexamethasone 13Bortezomib 8Cyclophosphamide 5Lenalidomide 4pomalidomide 3isatuximab 3Calcium Dobesilate 3Thalidomide 2Kidney Transplantation 2melflufen 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1belantamab mafodotin 1auricularum 1Zoledronic Acid 1Whole-Body Irradiation 1Tablets 1Ranitidine 1Plasmapheresis 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Drug Therapy 1Doxorubicin 1Diphenhydramine 1Data Collection 1Cyclosporine 1Bendamustine Hydrochloride 1BHQ880 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Insufficiency × daratumumab × Plasma cell × Clear all
NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Emory University

Phase 2 Terminated
17 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡